Biomx Inc Stock Price, News & Analysis

BiomX (NYSE: PHGE) reported significant progress in Q1 2025, highlighted by positive Phase 2 trial results for BX211 in treating diabetic foot osteomyelitis (DFO). The trial demonstrated statistically significant improvements in ulcer size reduction and depth compared to placebo. BX211's development has been supported by $40 million in non-dilutive funding from the U.S. Defense Health Agency.

The company's BX004 Phase 2b study in Cystic Fibrosis remains on track for topline results in Q1 2026. In April 2025, shareholders approved warrant exercises from $12 million in financings announced in February 2025. The company's cash balance stood at $21.2 million as of March 31, 2025, with runway expected through Q1 2026. Q1 2025 financial results showed a net loss of $7.7 million, improved from $17.3 million in Q1 2024.

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has scheduled its first quarter 2025 financial results conference call and webcast for Thursday, May 15, 2025, at 2:00 p.m. ET. During the call, the company will discuss Q1 2025 financial performance and provide updates on its business operations and programs. Interested participants can join via phone by dialing 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The webcast will be accessible through the Investors section of BiomX's website at www.biomx.com, where it will also be archived for future viewing.

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on phage therapies, has disclosed that its independent registered public accounting firm included a going concern qualification in their audit opinion for the fiscal year ended December 31, 2024. This disclosure, which was previously included in the Company's annual report on Form 10-K filed on March 25, 2025, is being announced separately to comply with NYSE American Company Guide Sections 401(h) and 610(b). The company emphasizes that this announcement does not represent any changes or amendments to their 2024 audited financial statements or annual report.

BiomX (NYSE: PHGE) announced positive topline results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO). The trial demonstrated that BX211 was safe and well-tolerated, producing statistically significant improvements in multiple areas:

• Sustained reduction in ulcer size (PAR) with p=0.046 at week 12
• Significant improvements in ulcer depth at week 13 (p=0.048)
• Reduced expansion of ulcer area (p=0.017)

The study involved 41 patients randomized at a 2:1 ratio, with 26 receiving BX211 and 15 receiving placebo. Treatment showed separation from placebo starting at week 7, with a difference greater than 40% by week 10. The company is now planning for a Phase 2/3 trial, pending FDA feedback.

BiomX (NYSE: PHGE) announced its Q4 and full year 2024 financial results, highlighting key developments in its phage therapy programs. The company secured $12 million in financing in February 2025 to support its Phase 2b study of BX004. Key financial metrics include:

- Cash balance of $18.0 million as of December 31, 2024
- R&D expenses increased to $24.7 million in 2024
- Net loss decreased to $17.7 million in 2024
- Operating cash burn of $37 million in 2024

Clinical Updates:

• BX211 Phase 2 topline results for diabetic foot osteomyelitis expected by end of March 2025
• BX004 Phase 2b topline results for cystic fibrosis anticipated in Q1 2026
• Received $36.8 million in non-dilutive funding from DHA for BX211 trial

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria, has announced it will release its fourth quarter and full year 2024 financial results on March 25, 2025.

The financial results will be accessible through a press release in the Investors section of BiomX's website. The company plans to host a conference call and audio webcast at a later date, which will coincide with the announcement of initial topline results from its Phase 2 trial investigating treatments for subjects with diabetic foot osteomyelitis.

BiomX Inc. (NYSE American: PHGE) has secured $12 million in financing through a series of offerings, including a registered direct offering and concurrent private placement. The funding will support the advancement of their BX004 program through Phase 2b study in cystic fibrosis patients, with topline results expected in Q1 2026.

The offerings were led by Deerfield Management Company with significant participation from the Cystic Fibrosis Foundation and Nantahala Capital. The financing includes the purchase of 3,633,514 shares of common stock at $0.9306 per share, along with warrants for additional shares. The company will also analyze real-world evidence exploring the relationship between P. aeruginosa reduction and clinical outcomes in CF patients.

BiomX Inc. (NYSE American: PHGE), a clinical-stage company focusing on phage therapies targeting specific pathogenic bacteria, announced that it has received a written notification from NYSE American , dated December 10, 2024. The notification confirms that BiomX has regained compliance with all NYSE American continued listing standards. This compliance rectifies the deficiencies noted on May 23, 2024, as outlined in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. NYSE American verified that BiomX has met the continued listing standards for two consecutive quarters, in accordance with Section 1009(f) of the Company Guide.

BiomX announced Q3 2024 financial results and clinical program updates. Patient enrollment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is complete, with topline results expected in Q1 2025. The BX004 Phase 2b study in Cystic Fibrosis faced manufacturing delays, now resolved, with results expected in H1 2026. Cash balance was $24.7M as of September 30, 2024. R&D expenses increased to $7.3M from $5.6M year-over-year. The company reported net income of $9.6M compared to a net loss of $7.9M in Q3 2023, mainly due to changes in warrant fair value. Cash runway extends into Q4 2025.